| NCT ID | NCT03033914 |
| Title | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | no |
| Sponsors | Memorial Sloan Kettering Cancer Center |
| Indications | |
| Therapies |
Dacarbazine + Doxorubicin + Vinblastine + Nivolumab Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab |
| Age Groups: | adult senior |